Copy of News Paper publication for Audited financial results for the quarter and financial year ended 31st March,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Limited has published its audited standalone and consolidated financial results for Q4 FY25 and full year ended 31st March 2025 in Financial Express and Prajashakti, as required under SEBI LODR Regulation 47. On a standalone basis, total income fell to Rs 796.89 lakhs in Q4 FY25 (vs Rs 1,446.67 lakhs in Q4 FY24) and full-year income declined to Rs 3,694.65 lakhs from Rs 4,327.00 lakhs. Standalone net profit for the year dropped to Rs 29.57 lakhs (vs Rs 41.95 lakhs in FY24), with Q4 standalone PAT at just Rs 0.80 lakhs. On a consolidated basis, full-year revenue edged up to Rs 4,525.91 lakhs (from Rs 4,493.38 lakhs) but net profit fell to Rs 33.62 lakhs (from Rs 47.25 lakhs), and the company slipped into a loss of Rs 2.67 lakhs in Q4 FY25.
The results show weak top-line growth and a sharp slowdown in profitability, with the company reporting a consolidated quarterly loss. For shareholders, this signals continued margin pressure and stagnant earnings momentum, which is unlikely to be viewed positively by the market in the near term.